Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialFrancesco Schettini, Daniele Generali, Giuseppina Barbieri et al.|Frontiers in Oncology|2021Cited by 19
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of LiteratureOttavia Bernocchi, Daniele Generali, Marianna Sirico et al.|Pharmaceuticals|2021Cited by 12
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving OlaparibFrancesco Schettini, Daniele Generali, Maria Valeria De Bonis et al.|Scientific Reports|2023Cited by 6
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational studyFrancesco Schettini, Daniele Generali, Marianna Sirico et al.|The Oncologist|2024Cited by 6
Next-Generation Sequencing-Based Evaluation of the Actionable Mutational Landscape in Solid Tumors: the “MOZART” Prospective Observational StudyFrancesco Schettini, Daniele Generali, Marianna Sirico et al.|Research Square|2024Cited by 0